Poster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1 inhibitor CHICAGO--(BUSINESS WIRE)--Schrödinger, ...
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR ...
Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 The SGR-3515 presentation will include data demonstrating that an optimized, intermittent dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results